Does Crocin Cognition Randomized Trial work?

Updated October 2026

Quick Answer

Crocin Cognition Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: In aged mice, the low dose prevented age-related weight loss and modulated hepatic lipid metabolism, whereas the high dose reduced anxiety-like behavior and improved recognition memory.

Key Takeaways

  • 01In aged mice, the low dose prevented age-related weight loss and modulated hepatic lipid metabolism, whereas the high dose reduced anxiety-like behavior and improved recognition memory. [Navarro JA (2026)]
  • 02The anxiolytic effects are consistent with elevated hypothalamic Npy , an anxiolytic peptide, reduced amygdalar Crh , a key mediator of stress and anxiety, and decreased hypothalamic Hcrt, an arousal modulator. [Navarro JA (2026)]
  • 03The improvement in memory is associated with modulation of the cortical and hippocampal inflammatory and endocannabinoid proteins involved in neural plasticity. [Navarro JA (2026)]
  • 04Background : Population aging increases susceptibility to cognitive decline, anxiety, and metabolic dysregulation, yet safe and effective interventions remain limited. [Navarro JA (2026)]
The current Migaku evidence database contains 2 reusable source documents for Crocin Cognition Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - In aged mice, the low dose prevented age-related weight loss and modulated hepatic lipid metabolism, whereas the high dose reduced anxiety-like behavior and improved recognition memory. [Navarro JA (2026); evidence level 4] - The anxiolytic effects are consistent with elevated hypothalamic Npy , an anxiolytic peptide, reduced amygdalar Crh , a key mediator of stress and anxiety, and decreased hypothalamic Hcrt, an arousal modulator. [Navarro JA (2026); evidence level 4] - The improvement in memory is associated with modulation of the cortical and hippocampal inflammatory and endocannabinoid proteins involved in neural plasticity. [Navarro JA (2026); evidence level 4] - Background : Population aging increases susceptibility to cognitive decline, anxiety, and metabolic dysregulation, yet safe and effective interventions remain limited. [Navarro JA (2026); evidence level 4] - There is currently no approved treatment for slowing cognitive decline in MS, aside from the benefits associated with disease-modifying treatments. [Rezaei Ali (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Safranal-Standardized Saffron Extract Improves Metabolic, Cognitive, and Anxiolytic Outcomes in Aged Mice via Hypothalamic-Amygdalar Peptide Modulation.
  2. Can supplementation with antioxidants improve cognitive functions in patients with multiple sclerosis? A literature review